Management of inflammatory cardiopulmonary manifestations in systemic lupus erythematosus: a systematic review

医学 美罗华 心包炎 心肌炎 肺动脉高压 重症监护医学 抗磷脂综合征 间质性肺病 急性心包炎 红斑狼疮 内科学 环磷酰胺 系统性红斑狼疮 过敏性肺炎 皮肤病科 任天堂 系统回顾 免疫学 心脏病学 肺 隐源性机化性肺炎 强的松 外科
作者
Yanjie Hao,Ricardo Montes,Shereen Oon,Mandana Nikpour
出处
期刊:Revista Brasileira De Reumatologia [Elsevier BV]
卷期号:66 (1)
标识
DOI:10.1186/s42358-026-00551-1
摘要

BACKGROUND: Cardiopulmonary involvement in systemic lupus erythematosus (SLE) refers to a group of serious manifestations, with a high prevalence for some, such as pericarditis and pleuritis, and high mortality in others, such as lupus myocarditis (LM) and diffuse alveolar haemorrhage (DAH). There is a paucity of systematic literature reviews on the management of inflammatory cardiopulmonary manifestations in SLE. We aimed to assess the available evidence in this area. METHODS: A systematic literature search was conducted from January 1990 to June 2025 using keywords related to the cardiac and pulmonary systems, SLE, and treatments. Manifestations related to atherosclerosis or anti-phospholipid syndrome were excluded. RESULTS: A total of 67 studies, covering pericarditis, LM, pulmonary arterial hypertension (PAH), pleuritis, acute lupus pneumonitis (ALP), DAH, interstitial lung disease, and shrinking lung syndrome (SLS) were included. Glucocorticoids (GCs) were utilized as first-line treatment for all these conditions, and GC pulse was commonly administered in serious manifestations such as pericardial tamponade, LM, ALP, and DAH. Cyclophosphamide was the most used immunosuppressant, with low-to-moderate evidence indicating its effectiveness. Low-to-moderate evidence supported rituximab as a second-line therapy for LM, DAH, and SLS, and plasma exchange was commonly used in DAH. For PAH, high-quality evidence from RCTs supported the use of PAH-targeted therapies, and initial PAH-targeted combination therapy showed more benefits than monotherapy. In addition, immunosuppressive therapy may be beneficial for SLE-PAH patients, especially those with early, mild PAH. Anti-fibrotic therapy, such as nintedanib and pirfenidone, had no evidence of effectiveness in SLE-ILD. Evidence for the benefit of belimumab and anifrolumab for cardiopulmonary manifestations was also minimal. Patients with some conditions, such as LM, ALP, and DAH, had poor prognoses under current therapies, with reported short-term mortalities of up to 40%-60%. CONCLUSIONS: GC and conventional IS currently remain the most evidence-based approaches for managing most cardiopulmonary manifestations in SLE. Despite aggressive immunosuppressive therapies, patients with some conditions, such as LM, ALP, and DAH, still experience high mortality. The quality of the existing evidence and the insights into novel therapies in these patients were limited, highlighting the urgent need for RCTs and optimized management in this area.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Karma完成签到,获得积分10
刚刚
1秒前
111完成签到,获得积分10
1秒前
含蓄平蓝完成签到 ,获得积分10
1秒前
LIUJIAWEI发布了新的文献求助10
2秒前
jachin完成签到 ,获得积分10
3秒前
简单山水发布了新的文献求助10
4秒前
4秒前
4秒前
李茗慧完成签到 ,获得积分10
4秒前
忆修完成签到,获得积分10
6秒前
Hello的应助被zhu采纳,获得10
6秒前
毕业就摆烂完成签到,获得积分20
7秒前
朴素的伟诚完成签到,获得积分10
9秒前
yanxiaoling发布了新的文献求助10
9秒前
9秒前
申晨曦完成签到 ,获得积分10
9秒前
9秒前
zzzxl完成签到,获得积分10
9秒前
Hello的应助被小艾同学采纳,获得10
10秒前
沉默诗兰完成签到,获得积分10
10秒前
王君青见完成签到,获得积分10
11秒前
11完成签到,获得积分10
13秒前
13秒前
song完成签到 ,获得积分10
13秒前
王敏完成签到 ,获得积分10
13秒前
山里万重完成签到,获得积分10
14秒前
Juvenilesy的应助被傻傻的起眸采纳,获得10
14秒前
14秒前
14秒前
和谐的寒风完成签到,获得积分20
14秒前
王长长完成签到,获得积分10
15秒前
15秒前
英姑的应助被brokey采纳,获得10
16秒前
xuhangming完成签到,获得积分20
18秒前
18秒前
jack完成签到,获得积分10
18秒前
20秒前
糜康发布了新的文献求助10
21秒前
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181658
求助须知:如何正确求助?哪些是违规求助? 9571454
关于积分的说明 21818081
捐赠科研通 7777987
什么是DOI,文献DOI怎么找? 3433508
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479568